• 1
    Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995; 75: 218695.
  • 2
    Metzger ML, Dome JS. Current therapy for Wilms' tumor. Oncologist 2005; 10: 81526.
  • 3
    Breslow N, Olshan A, Beckwith JB, Green DM. Epidemiology of Wilms tumor. Med Pediatr Oncol 1993; 21: 17281.
  • 4
    Kyambi JM, Kasili EG, Onyango JN, Kitonyi GW. The management of Wilms' tumour in Kenya. East Afr Med J 1981; 58: 42430.
  • 5
    Kasili EG, Kyambi JM, Onyango JN, Kitonyi GW, Owade JN, Njenga GJ. Nephroblastoma: an example of cancer curable by appropriate intervention even in developing countries. East Afr Med J 1987; 64: 82835.
  • 6
    Abdallah FK, Macharia WM. Clinical presentation and treatment outcome in children with nephroblastoma in Kenya. East Afr Med J 2001; 78: S43S47.
  • 7
    Ekenze SO, Agugua-Obianyo NE, Odetunde OA. The challenge of nephroblastoma in a developing country. Ann Oncol 2006; 17: 1598600.
  • 8
    Wilde JC, Lameris W, van Hasselt EH, Molyneux EM, Heij HA, Borgstein EG. Challenges and outcome of Wilms' tumour management in a resource-constrained setting. Afr J Paediatr Surg 2010; 7: 15962.
  • 9
    Israels T, Ribeiro RC, Molyneux EM. Strategies to improve care for children with cancer in Sub-Saharan Africa. Eur J Cancer 2010; 46: 19606.
  • 10
    Davidoff AM. Wilms' tumor. Curr Opin Pediatr 2009; 21: 35764.
  • 11
    Faria P, Beckwith JB, Mishra K, Zuppan C, Weeks DA, Breslow N, Green DM. Focal versus diffuse anaplasia in Wilms tumor—new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol 1996; 20: 90920.
  • 12
    Beckwith JB. National Wilms Tumor Study: an update for pathologists. Pediatr Dev Pathol 1998; 1: 7984.
  • 13
    Beckwith JB, Zuppan CE, Browning NG, Moksness J, Breslow NE. Histological analysis of aggressiveness and responsiveness in Wilms' tumor. Med Pediatr Oncol 1996; 27: 4228.
  • 14
    Hill DA, Shear TD, Liu T, Billups CA, Singh PK, Dome JS. Clinical and biologic significance of nuclear unrest in Wilms tumor. Cancer 2003; 97: 231826.
  • 15
    Govender D, Harilal P, Hadley GP, Chetty R. p53 protein expression in nephroblastomas: a predictor of poor prognosis. Br J Cancer 1998; 77: 31418.
  • 16
    Sredni ST, de Camargo B, Lopes LF, Teixeira R, Simpson A. Immunohistochemical detection of p53 protein expression as a prognostic indicator in Wilms tumor. Med Pediatr Oncol 2001; 37: 4558.
  • 17
    Beniers AJ, Efferth T, Fuzesi L, Granzen B, Mertens R, Jakse G. p53 expression in Wilms' tumor: a possible role as prognostic factor. Int J Oncol 2001; 18: 1339.
  • 18
    Ghanem MA, Van der Kwast TH, Sudaryo MK, Mathoera RB, van den Heuvel MM, Al-Doray AA, Nijman RM, van Steenbrugge GJ. MIB-1 (Ki-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma. Clin Cancer Res 2004; 10: 5917.
  • 19
    Nusse R. Cancer. Converging on β-catenin in Wilms tumor. Science 2007; 316: 9889.
  • 20
    Koesters R, Niggli F, von Knebel Doeberitz M, Stallmach T. Nuclear accumulation of β-catenin protein in Wilms' tumours. J Pathol 2003; 199: 6876.
  • 21
    Provost E, Yamamoto Y, Lizardi I, Stern J, D'Aquila TG, Gaynor RB, Rimm DL. Functional correlates of mutations in β-catenin exon 3 phosphorylation sites. J Biol Chem 2003; 278: 317819.
  • 22
    Ehrlich D, Bruder E, Thome MA, Gutt CN, von Knebel Doeberitz M, Niggli F, Perantoni AO, Koesters R. Nuclear accumulation of β-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas. Pediatr Dev Pathol 2010; 13: 18.
  • 23
    Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW, Murty VV, Grundy PE, Fearon ER, D'Agati V, Licht JD, et al. CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 2004; 165: 194353.
  • 24
    Fukuzawa R, Anaka MR, Weeks RJ, Morison IM, Reeve AE. Canonical WNT signalling determines lineage specificity in Wilms tumour. Oncogene 2009; 28: 106375.
  • 25
    Fukuzawa R, Heathcott RW, More HE, Reeve AE. Sequential WT1 and CTNNB1 mutations and alterations of β-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol 2007; 60: 101316.
  • 26
    Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, Angers S, Moon RT. Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling. Science 2007; 316: 10436.
  • 27
    Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008; 47: 46170.
  • 28
    Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, Friedman R, Klein U, Tycko B. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 2002; 160: 218190.
  • 29
    Boyle S, Shioda T, Perantoni AO, de Caestecker M. Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis. Dev Dyn 2007; 236: 232130.
  • 30
    Kobayashi A, Valerius MT, Mugford JW, Carroll TJ, Self M, Oliver G, McMahon AP. Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell 2008; 3: 16981.
  • 31
    Hendry C, Rumballe B, Moritz K, Little MH. Defining and redefining the nephron progenitor population. Pediatr Nephrol 2011; 26: 1395406. Epub 2011 Jan 14. Review.
  • 32
    Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND, Bard JBL. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech Dev 1993; 40: 8597.
  • 33
    Kreidberg JA. WT1 and kidney progenitor cells. Organogenesis 2010; 6: 6170.
  • 34
    Vuononvirta R, Sebire NJ, Dallosso AR, Reis-Filho JS, Williams RD, Mackay A, Fenwick K, Grigoriadis A, Ashworth A, Pritchard-Jones K, Brown KW, Vujanic GM, et al. Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. Clin Cancer Res 2008; 14: 763544.
  • 35
    Lovvorn HN, Westrup J, Opperman S, Boyle S, Shi G, Anderson J, Perlman EJ, Perantoni AO, Wills M, de Caestecker M. CITED1 expression in Wilms' tumor and embryonic kidney. Neoplasia 2007; 9: 589600.
  • 36
    Groseclose MR, Massion PP, Chaurand P, Caprioli RM. High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 2008; 8: 371524.
  • 37
    Axt J, Murphy AJ, Seeley EH, Martin CA, Taylor C, Pierce J, Caprioli RM, Whiteside M, Lovvorn HN. Race disparities in Wilms tumor incidence and biology. J Surg Res 2011; 170: 11219.
  • 38
    Wegert J, Bausenwein S, Roth S, Graf N, Geissinger E, Gessler M. Characterization of primary Wilms tumor cultures as an in vitro model. Genes Chromosomes Cancer 2012; 51: 92104.
  • 39
    Perlman EJ, Grundy PE, Anderson JR, Jennings LJ, Green DM, Dome JS, Shamberger RC, Ruteshouser EC, Huff V. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: a children's oncology group study. J Clin Oncol 2011; 29: 698703.
  • 40
    Royer-Pokora B, Busch M, Beier M, Duhme C, de Torres C, Mora J, Brandt A, Royer HD. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. Hum Mol Genet 2010; 19: 165168.
  • 41
    Seeley EH, Caprioli RM. Molecular imaging of proteins in tissues by mass spectrometry. Proc Natl Acad Sci USA 2008; 105: 1812631.
  • 42
    Lahoti C, Thorner P, Malkin D, Yeger H. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Am J Pathol 1996; 148: 157789.
  • 43
    Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994; 7: 917.
  • 44
    Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch BA, Franklin JL, Lange B, Gamis AS, et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol 2011; 29: 70411.
  • 45
    Orloff MS, Iyengar SK, Winkler CA, Goddard KA, Dart RA, Ahuja TS, Mokrzycki M, Briggs WA, Korbet SM, Kimmel PL, Simon EE, Trachtman H, et al. Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiol Genomics 2005; 21: 21221.
  • 46
    Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar A, Stewart J, Strong LC, Behringer RR, Huff V. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest 2011; 121: 17483.
  • 47
    Murphy AJ, Pierce J, de Caestecker C, Taylor C, Anderson JR, Perantoni AO, de Caestecker MP, Lovvorn HN. SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms tumor. J Pediatr Surg, in press.